Top

Published in:

01-08-2016 | Original Scientific Report

Adjuvant I-131 Lipiodol After Resection or Radiofrequency Ablation for Hepatocellular Carcinoma

Authors: Lilian Schwarz, Michael Bubenheim, Isabelle Gardin, Emmanuel Huet, Ghassan Riachi, Erick Clavier, Odile Goria, Pierre Vera, Michel Scotté

Published in: World Journal of Surgery | Issue 8/2016

Abstract

Background and objectives

High rates of recurrence have been observed after curative treatment for hepatocellular carcinoma (HCC). The main aim of this study was to establish the influence of adjuvant transarterial radioembolization-based I-131 lipiodol on survival and recurrence.

Methods

Between 2004 and 2010, 38 patients were treated with adjuvant I-131 lipiodol therapy, at a dosage of 2220 MBq, within 4 months after surgery. This treated cohort was compared to a control cohort consisting of 42 consecutive patients operated prior to the time the I-131 lipiodol treatment became available.

Results

Recurrence-free survival in the control and in the I-131 lipiodol cohort was 12.6 and 18.7 months, respectively (HR = 1.871, p = 0.025). At 2 and 5 years, the cumulative incidence of a first recurrence or death was, respectively, 50 % and 61 % in the treated cohort versus 69 % and 74 % in the control cohort. Median overall survival was 55 and 29 months, respectively (p = 0.051). Among patients with a recurrence at 2 years, more patients had already experienced such recurrence at 1 year in the control cohort (70 % vs 33 %, p = 0.014).

Conclusions

Adjuvant I-131 lipiodol improves disease-free survival in patients with HCC.

Bruix J, Sherman M (2005) Practice guidelines committee AAftSoLD management of hepatocellular carcinoma. Hepatology 42(1208–123):6

Jelic S (2010) Sotiropoulos GC. Group EGW Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up annals of oncology : official journal of the European Society for Medical Oncology/ESMO 21(Suppl 5):v59–v64CrossRef

Huang J, Yan L, Cheng Z et al (2010) A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria Annals of surgery 252(903–91):2

Liu JG, Wang YJ, Du Z (2010) Radiofrequency ablation in the treatment of small hepatocellular carcinoma: a meta analysis. World J Gastroenterol 16(3450–345):6

Lai EC, Lau WY (2005) The continuing challenge of hepatic cancer in Asia Surgeon. The Surgeon 3(210–21):5

Llovet JM, Burroughs A (2003) Hepatocellular carcinoma. Lancet 362(1907–191):7

Belghiti J, Panis Y, Farges O et al (1991) Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg 214(114–11):7

Ercolani G, Grazi GL, Ravaioli M et al (2003) Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg 237(536–54):3

Tanaka H, Kubo S, Tsukamoto T et al (2005) Recurrence rate and transplantability after liver resection in patients with hepatocellular carcinoma who initially met transplantation criteria. Transpl Proc 37(1254–125):6

10.

Poon RT, Fan ST, Ng IO et al (2000) Significance of resection margin in hepatectomy for hepatocellular carcinoma: a critical reappraisal. Ann Surg 231(544–55):1

11.

Zhong JH, Li H, Li LQ et al (2012) Adjuvant therapy options following curative treatment of hepatocellular carcinoma: a systematic review of randomized trials. Eur J Surg Oncol 38(286–29):5

12.

Li JQ, Zhang YQ, Zhang WZ et al (1995) Randomized study of chemoembolization as an adjuvant therapy for primary liver carcinoma after hepatectomy. J Cancer Res Clin Oncol 121(364–36):6

13.

Peng BG, He Q, Li JP et al (2009) Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Surg 198(313–31):8

14.

Yoo HS, Park CH, Lee JT et al (1994) Small hepatocellular carcinoma: high dose internal radiation therapy with superselective intra-arterial injection of I-131-labeled Lipiodol. Cancer Chemother Pharmacol 33(Suppl):S128–S133CrossRefPubMed

15.

Lau WY, Leung TW, Ho SK et al (1999) Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet 353:797–801CrossRefPubMed

16.

Lau WY, Lai EC, Leung TW et al (2008) Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5 year and 10 year survival. Ann Surg 247:43–48CrossRefPubMed

17.

Kalbfleisch JD, Prentice RL (1980) The statistical analysis of failure time data New York. Wiley, New York

18.

Lau WY (2002) Management of hepatocellular carcinoma. J R Coll Surg Edinb 47:389–399PubMed

19.

Shimada M, Takenaka K, Gion T et al (1996) Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan. Gastroenterology 111:720–726CrossRefPubMed

20.

Shi M, Zhang CQ, Zhang YQ et al (2004) Micrometastases of solitary hepatocellular carcinoma and appropriate resection margin. World J Surg 28(376–38):1

21.

Wong IH, Yeo W, Leung T et al (2001) Circulating tumor cell mRNAs in peripheral blood from hepatocellular carcinoma patients under radiotherapy, surgical resection or chemotherapy: a quantitative evaluation. Cancer Lett 167:183–191CrossRefPubMed

22.

Fan ST, Yang ZF, Ho DW et al (2011) Prediction of posthepatectomy recurrence of hepatocellular carcinoma by circulating cancer stem cells: a prospective study. Ann Surg 254(569–57):6

23.

Poon RT, Fan ST, Ng IO et al (2000) Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 89(500–50):7

24.

Lau WY, Lai EC, Lau SH (2009) The current role of neoadjuvant/adjuvant/chemoprevention therapy in partial hepatectomy for hepatocellular carcinoma: a systematic review. Hepat Pancreat Dis Int 8:124–133

25.

Madsen MT, Park CH, Thakur ML (1988) Dosimetry of iodine-131 ethiodol in the treatment of hepatoma. J Nucl Med 29:1038–1044PubMed

26.

Lui WY, Liu RS, Chiang JH et al (1990) Report of a pilot study of intra-arterial injection of I-131 lipiodol for the treatment of hepatoma. Zhonghua Yi Xue Za Zhi (Taipei) 46:125–133

27.

Chung AY, Ooi LL, Machin D et al (2013) Adjuvant hepatic intra-arterial iodine-131-lipiodol following curative resection of hepatocellular carcinoma: a prospective randomized trial. World J Surg 37:1356–1361CrossRefPubMed

28.

Dumortier J, Decullier E, Hilleret MN et al (2014) Adjuvant intraarterial lipiodol or 131I-lipiodol after curative treatment of hepatocellular carcinoma: a prospective randomized trial. J Nucl Med 55:877–883CrossRefPubMed

29.

Boucher E, Bouguen G, Garin E et al (2008) Adjuvant intraarterial injection of 131I-labeled lipiodol after resection of hepatocellular carcinoma: progress report of a case-control study with a 5-year minimal follow-up. J Nucl Med 49:362–366CrossRefPubMed

30.

Chua TC, Chu F, Butler SP et al (2010) Intra-arterial iodine-131-lipiodol for unresectable hepatocellular carcinoma. Cancer 116:4069–4077CrossRefPubMed

31.

Tabone M, Vigano L, Ferrero A et al (2007) Prevention of intrahepatic recurrence by adjuvant (131)iodine-labeled lipiodol after resection for hepatocellular carcinoma in HCV-related cirrhosis. Eur J Surg Oncol 33:61–66CrossRefPubMed

32.

Ng KM, Niu R, Yan TD et al (2008) Adjuvant lipiodol I-131 after curative resection/ablation of hepatocellular carcinoma. HPB 10:388–395CrossRefPubMedPubMedCentral

33.

Partensky C, Sassolas G, Henry L et al (2000) Intra-arterial iodine 131-labeled lipiodol as adjuvant therapy after curative liver resection for hepatocellular carcinoma: a phase 2 clinical study. Arch Surg 135:1298–1300CrossRefPubMed

34.

Furtado R, Crawford M, Sandroussi C (2014) Systematic review and meta-analysis of adjuvant i(131) lipiodol after excision of hepatocellular carcinoma. Ann Surg Oncol 21:2700–2707CrossRefPubMed

35.

Gong L, Shi L, Sun J et al (2014) Comparative survival analysis of adjuvant therapy with iodine-131-labeled lipiodol to hepatic resection of primary hepatocellular carcinoma: a meta-analysis. Nucl Med Commun 35:484–492CrossRefPubMed

36.

Tabone M, Vigano L, Laudi et al.(2005) Adjuvant iodine-131-labeled lipiodol for prevention of intrahepatic recurrence of hepatocellular carcinoma: which is the best treatment schedule? Hepatology: 41, 1433; author reply 1433–1434

37.

Raoul JL, Boucher E, Roland V et al (2009) 131-iodine Lipiodol therapy in hepatocellular carcinoma. Q J Nucl Med Mol Imaging 53:348–355PubMed

38.

Oger E, Lavenu A, Bellissant E et al (2011) Meta-analysis of interstitial pneumonia in studies evaluating iodine-131-labeled lipiodol for hepatocellular carcinoma using exact likelihood approach. Pharmacoepidemiol Drug Saf 20:956–963PubMed

Title: Adjuvant I-131 Lipiodol After Resection or Radiofrequency Ablation for Hepatocellular Carcinoma
Authors: Lilian Schwarz
Michael Bubenheim
Isabelle Gardin
Emmanuel Huet
Ghassan Riachi
Erick Clavier
Odile Goria
Pierre Vera
Michel Scotté
Publication date: 01-08-2016
Publisher: Springer International Publishing
Published in: World Journal of Surgery / Issue 8/2016
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI: https://doi.org/10.1007/s00268-016-3502-5

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Adjuvant I-131 Lipiodol After Resection or Radiofrequency Ablation for Hepatocellular Carcinoma

Abstract

Background and objectives

Methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background and objectives

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2016

Anatomic Variability of the Upper Mediastinal Lymph Node Level VII

What Kind of Incision Should Be Used in Thoracic Trauma Patients in Emergent Cases? Reply

Usefulness of Preoperative Plasma Fibrinogen Versus Other Prognostic Markers for Predicting Gastric Cancer Recurrence

Surgical Non-governmental Organizations: Global Surgery’s Unknown Nonprofit Sector

Amputation Versus Limb-Salvage Surgery in Patients with Osteosarcoma: A Meta-analysis

Impact of p53 and PDGFR-β Expression on Metastasis and Prognosis of Patients with Pancreatic Cancer